Kiva Ariani Fisher

Kiva Ariani Fisher

Auto-generated profile, based on publicly available information

Kiva Ariani Fisher

Division of Global HIV and TB, Center for Global Health, U.S. Centers for Disease Control and Prevention, Lusaka, Zambia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
KFKiva A. Fisher
Kiva A. Fisher
JBJohn P. Barile
John P. Barile
RGRebecca J. Guerin
Rebecca J. Guerin
KEKayla L. Vanden Esschert
Kayla L. Vanden Esschert
AJAlexiss Jeffers
Alexiss Jeffers
CPChristine E. Prue
Christine E. Prue
This report describes the rates of cloth face covering use among U.S. adults in April and May 2020.

6 November 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
KFKiva A. Fisher
Kiva A. Fisher
This report describes the impact of telework on risk for SARS-CoV-2 infection.

6 January 2021 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
KFKiva A. Fisher
Kiva A. Fisher
SOSamantha M. Olson
Samantha M. Olson
MTMark W. Tenforde
Mark W. Tenforde
WSWesley H. Self
Wesley H. Self
MWMichael Wu
Michael Wu
LFLeora R. Feldstein
Leora R. Feldstein
Background: Symptoms of mild COVID‐19 illness are non‐specific and may persist for prolonged periods. Effects on quality of life of persistent poor physical or mental health associated with COVID‐19 are not well understood.Methods: Adults aged ≥18 years with laboratory‐confirmed COVID‐19 and matched control patients who tested negative for SARS‐CoV‐2 infection at outpatient facilities associated with 11 medical centers in the United States were interviewed to assess symptoms, illness duration, and health‐related quality of life. Duration of symptoms, health‐related quality of life measures, and days of poor physical health by symptoms experienced during illness were compared between case patients and controls using Wilcoxon rank‐sum tests. Symptoms associated with COVID‐19 case status were evaluated by multivariable logistic regression.Results: Among 320 participants included, 157 were COVID‐19 cases and 163 were SARS‐CoV‐2 negative controls. Loss of taste or smell was reported by 63% of cases and 6% of controls and was strongly associated with COVID‐19 in logistic regression models (adjusted odds ratio [aOR] = 32.4; 95% confidence interval [CI], 12.6‐83.1). COVID‐19 cases were more likely than controls to have experienced fever, body aches, weakness, or fatigue during illness, and to report ≥1 persistent symptom more than 14 days after symptom onset (50% vs 32%, P < .001). Cases reported significantly more days of poor physical health during the past 14 days than controls (P < .01).Conclusions: Differentiating COVID‐19 from other acute illnesses will require widespread diagnostic testing, especially during influenza seasons. Persistent COVID‐19‐related symptoms may negatively affect quality of life, even among those initially presenting with mild illness.

25 March 2022 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
KFKiva A. Fisher
Kiva A. Fisher
This report describes programmatic gains of HIV treatment during the pandemic.

27 April 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KFKiva Ariani Fisher
Kiva Ariani Fisher
LCLaura Michele Cahill
Laura Michele Cahill
SBStephanie Broyles
Stephanie Broyles
MRMarion Rorke
Marion Rorke
WRWilliam Thomas Robinson
William Thomas Robinson
High-risk injection related behavior including use of non-sterile syringes is associated with negative health outcomes among people who inject drugs (PWID). Drug treatment programs have been reported to curb hepatitis C (HCV) transmission. This study aims to assess the role of drug treatment programs and knowledge of HCV status, and how they influence current injection-related risk. Data were collected in 2012 by the New Orleans arm of the CDC funded National HIV Behavioral Surveillance. Respondent driven sampling was used to recruit a sample of PWID. The analytic sample consisted of 473 participants. Univariate, bivariate, and linear regression analyses were performed. Findings indicated that history of drug treatment is associated with sterile syringe use among PWID. Further, knowledge of HCV status modifies the relationship between history of drug treatment and sterile syringe use in this sample. These findings highlight the importance of scaling up prevention efforts by expanding testing, counselling, and treatment for HCV among PWID who enter drug treatment facilities.

9 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KMKeith Mweebo
Keith Mweebo
AMAnnie Mwila
Annie Mwila
KTKiva F. Tinglof
Kiva F. Tinglof
MTMark W. Tenforde
Mark W. Tenforde
BMBrian Muyunda
Brian Muyunda
SASimon Agolory
Simon Agolory
Introduction Zambia has achieved ambitious programmatic targets of HIV diagnosis, treatment coverage, and viral load suppression among persons living with HIV (PLHIV) with the support of the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and other donors. Beginning in fiscal year (FY) 2019, U.S. CDC Zambia transitioned its PEPFAR Direct Service Delivery (DSD) support in Eastern, Lusaka, Southern, and Western Provinces from non-governmental organizations (NGOs) to a government to government (G2G) provincial health office (PHO) service delivery model for program ownership and sustainability. We reviewed programmatic and financial data during and after the period of this transition. Methods Programmatic performance using PEPFAR’s Monitoring, Evaluation, and Reporting and expenditure reporting data were used to assess changes over the period of transition from an NGO-led to government-led DSD model in Zambia. Data were reviewed across six FYs from October 2018 – September 2019 (FY19) through October 2023 – September 2024 (FY24) in four provinces across Zambia. Programmatic and expenditure performance indicators were analysed across time to assess PLHIV on antiretroviral therapy (ART), viral load coverage and suppression, and costs associated with care and treatment services. Results From FY19 to end of FY24, the number of PLHIV on ART across the four provinces increased by 31% (520,628 to 680,781). Viral load coverage and suppression in the transition provinces increased from 73% to 88% and 91% to 98%, respectively. Annual PEPFAR financial investments for care and treatment activities (in 2019 US dollars) increased by 25% ($12.7 million) from $38.3 million in FY19 to $51.0 million in FY21, as the amount invested in DSD increased concurrently with investments to implementing partners. From FY21 to FY24, spending declined by 41% ($21.1 million), while the total number of PLHIV on ART increased. The amount spent per PLHIV on ART decreased from $79 in FY21 to $44 in FY24, a decline of 44%. Conclusions The G2G model of service delivery and funding is an efficient and sustainable model for HIV epidemic control in Zambia. This government-led model shows a path forward to achieving sustainable HIV program success, reductions in costs, and expanded government ownership of the HIV program.